Russia allocates 33 million rubles to develop a new anaesthetic agent


By 2019, Russia will develop an anaesthetic agent for cancer patients, patients with acute myocardial infarction and coronary heart disease. According to the documents for the open tender of the Ministry of Education and Science, this new generation analgesic will be based on an artificially synthesized molecule and will not be addictive. To develop the medicine, the scientists will be allocated 33 million rubles from the state budget.

“The anaesthetics used in clinical practice do not meet all the requirements for efficiency and safety (gastro-, nephro-, hepato-, and hematotoxicity, development of addiction, etc.),” comments the Ministry of Education and Science.

According to available information, the analgesic will be based on derivatives of a substance known as “hexaazaisowurtzitane”. To date, there is no existing medicine that includes this substance. The molecule expected to become the base of new anaesthetic was synthesized artificially, and its analgesic properties have been discovered by Russian scientists while studying the biological properties of this compound.

Researchers at the Tomsk-based Goldberg Research Institute of Pharmacology and Regenerative Medicine and the Institute of Problems of Chemical Energy Technologies of the SB RAS have already started their pre-clinical studies.